Welcome to the MimoVax project
European Team led by AFFiRiS AG is developing Alzheimer’s Vaccine
The EU-project MimoVax aims to cure patients through vaccination. This could be the first safe and efficacious treatment to halt progression of this crippling disease.
The cornerstone of the new vaccination strategy is the proprietary AFFITOM® technology of AFFiRiS AG, a biotech company based in Vienna. Compared to conventional approaches AFFITOM® allows fast, cost-effective and safe vaccine development.
The project started in October 2006 with 2.4 M€ from the EC and a 2.0 M€ contribution by the participating SME. This three year STREP is coordinated by AFFiRiS AG and will conclude with a phase I clinical trial for the AD vaccine.
Project details
Download Fact sheet in English
Download Fact sheet auf Deutsch
Download Fact sheet en Español
( Adobe® Reader is required: download here)
Supported by the EC’s FP6 through Contract No. LSHB-CT-2006-037702
